Susanna  High net worth and biography

Susanna High Biography and Net Worth

Susanna has more than two decades of experience leading corporate strategy, portfolio management, business planning and operations for biotechnology companies. In her most recent position, she served as chief operating officer of bluebird bio where her numerous responsibilities included the advancement of the company’s severe genetic disease portfolio, leading to the European filing and then approval of ZYNTEGLO®, a gene therapy for the treatment of transfusion-dependent beta-thalassemia, as well as overseeing the build-out of its European organization. Before joining bluebird, Susanna worked in roles of increasing responsibility at Alnylam Pharmaceuticals, including as senior vice president, strategy and business integration, where she led corporate and portfolio strategy, program and alliance management, business planning and information technology. Previously, she supported corporate strategy and business operations at Millennium Pharmaceuticals (now Takeda Oncology). Susanna holds an M.S. in economics and business management from Bocconi University in Italy and an M.B.A. from the MIT Sloan School of Management.

What is Susanna High's net worth?

The estimated net worth of Susanna High is at least $4.47 million as of March 11th, 2024. Ms. High owns 156,800 shares of Dyne Therapeutics stock worth more than $4,468,800 as of March 28th. This net worth estimate does not reflect any other assets that Ms. High may own. Additionally, Ms. High receives a salary of $655,500.00 as COO at Dyne Therapeutics. Learn More about Susanna High's net worth.

How old is Susanna High?

Ms. High is currently 56 years old. There are 7 older executives and no younger executives at Dyne Therapeutics. The oldest executive at Dyne Therapeutics is Dr. Oxana Beskrovnaya Ph.D., Chief Scientific Officer, who is 62 years old. Learn More on Susanna High's age.

What is Susanna High's salary?

As the COO of Dyne Therapeutics, Inc., Ms. High earns $655,500.00 per year. The highest earning executive at Dyne Therapeutics is Mr. Joshua T. Brumm, CEO, President & Director, who commands a salary of $946,500.00 per year. Learn More on Susanna High's salary.

How do I contact Susanna High?

The corporate mailing address for Ms. High and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at [email protected]. Learn More on Susanna High's contact information.

Has Susanna High been buying or selling shares of Dyne Therapeutics?

During the last quarter, Susanna High has sold $100,031.75 in Dyne Therapeutics stock. Most recently, Susanna Gatti High sold 2,292 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $25.70, for a transaction totalling $58,904.40. Following the completion of the sale, the chief operating officer now directly owns 156,800 shares of the company's stock, valued at $4,029,760. Learn More on Susanna High's trading history.

Who are Dyne Therapeutics' active insiders?

Dyne Therapeutics' insider roster includes Joshua Brumm (CEO), Wildon Farwell (Insider), Susanna High (COO), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.

Are insiders buying or selling shares of Dyne Therapeutics?

During the last year, Dyne Therapeutics insiders bought shares 1 times. They purchased a total of 1,714,285 shares worth more than $29,999,987.50. During the last year, insiders at the sold shares 41 times. They sold a total of 2,466,517 shares worth more than $53,603,933.08. The most recent insider tranaction occured on March, 11th when insider Wildon Farwell sold 1,585 shares worth more than $40,734.50. Insiders at Dyne Therapeutics own 32.9% of the company. Learn More about insider trades at Dyne Therapeutics.

Information on this page was last updated on 3/11/2024.

Susanna High Insider Trading History at Dyne Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2024Sell2,292$25.70$58,904.40156,800View SEC Filing Icon  
3/7/2024Sell1,591$25.85$41,127.35186,291View SEC Filing Icon  
12/11/2023Sell1,616$10.72$17,323.52187,882View SEC Filing Icon  
11/2/2023Sell9,939$7.40$73,548.6094,605View SEC Filing Icon  
9/18/2023Sell2,672$9.41$25,143.52104,544View SEC Filing Icon  
9/12/2023Sell1,635$10.41$17,020.35107,216View SEC Filing Icon  
6/13/2023Sell1,625$12.43$20,198.75108,851View SEC Filing Icon  
3/14/2023Sell1,559$13.33$20,781.47110,476View SEC Filing Icon  
12/12/2022Sell751$10.87$8,163.37112,035View SEC Filing Icon  
3/11/2022Sell765$8.73$6,678.45View SEC Filing Icon  
9/23/2021Sell2,451$17.22$42,206.22View SEC Filing Icon  
See Full Table

Susanna High Buying and Selling Activity at Dyne Therapeutics

This chart shows Susanna Gatti High's buying and selling at Dyne Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dyne Therapeutics Company Overview

Dyne Therapeutics logo
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $28.50
Low: $26.81
High: $29.80

50 Day Range

MA: $23.77
Low: $15.62
High: $29.18

2 Week Range

Now: $28.50
Low: $6.40
High: $30.27

Volume

2,461,562 shs

Average Volume

1,871,726 shs

Market Capitalization

$2.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95